AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15661840 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise with local heating at 43 degrees C
Number of subjects: 0
Study 15661840 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise in hyperthermic condition
Number of subjects: 0
Study 12447292 — intervention group
Group type: EXPERIMENTAL
Intervention: Water instillation (500 to 1000 mL) at the beginning of the procedure
Number of subjects: 259
Study 12447292 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy (control group)
Number of subjects: 259
Study 10534595 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 52
Study 10534595 — intervention group
Group type: COMPARATOR
Intervention: Placebo needling
Number of subjects: 52
Study 7793821 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium supplementation
Number of subjects: 0
Study 7793821 — intervention group
Group type: COMPARATOR
Intervention: Active form of vitamin D3 (1,25(OH)2D3)
Number of subjects: 0
Study 7793821 — intervention group
Group type: COMPARATOR
Intervention: Synthetic analogue MC‐903
Number of subjects: 0
Study 7793821 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic analogue EB 1089
Number of subjects: 0
Study 7793821 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF
Number of subjects: 0
Study 2354386 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol (Omnipaque 350)
Number of subjects: 500
Study 2354386 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol (Isovue 370)
Number of subjects: 500
Study 2354386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate (Hexabrix 320)
Number of subjects: 500
Study 2354386 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial injections
Number of subjects: 500
Study 2354386 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral venous injections
Number of subjects: 500
Study 2354386 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous injections
Number of subjects: 500
Study 2354386 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of 80 patients with elevated baseline creatinine
Number of subjects: 500
Study 512017 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert modeling
Number of subjects: 24
Study 512017 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior rehearsal
Number of subjects: 24
Study 512017 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalization of assertive skills
Number of subjects: 24
Study 31382981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 1500 mg intravenously prior to skin incision
Number of subjects: 40
Study 31382981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 1500 mg intravenously after clamping of the umbilical cord
Number of subjects: 40
Study 31382981 — intervention group
Group type: COMPARATOR
Intervention: Vaginally born infants (control group)
Number of subjects: 40
Study 29477817 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid levels >7.2 mg/dl
Number of subjects: 6683
Study 29477817 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid levels ≥7 mg/dl
Number of subjects: 6683
Study 28925134 — intervention group
Group type: EXPERIMENTAL
Intervention: Longxue Tongluo capsule (two capsules each time, three times daily for 4 weeks)
Number of subjects: 160
Study 28925134 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two capsules each time, three times daily for 4 weeks)
Number of subjects: 160
Study 28925134 — intervention group
Group type: EXPERIMENTAL
Intervention: Longxue Tongluo capsule
Number of subjects: 160
Study 28925134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 25402168 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of regular‐fat dairy foods with reduced‐fat or low‐fat items
Number of subjects: 114
Study 25402168 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 114
Study 23072975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) for social anxiety disorder
Number of subjects: 0
Study 19293729 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion 1
Number of subjects: 51
Study 19293729 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion 2
Number of subjects: 51
Study 19293729 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 51
Study 17134770 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethazidine (TMZ) 20 mg, tds
Number of subjects: 30
Study 17134770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16794519 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scanning
Number of subjects: 32
Study 16794519 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 32
Study 16794519 — intervention group
Group type: EXPERIMENTAL
Intervention: MIBG scintigraphy
Number of subjects: 32
Study 16794519 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI + MIBG scintigraphy
Number of subjects: 32
Study 12085250 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 30
Study 12085250 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 30
Study 12085250 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy blood donors)
Number of subjects: 30
Study 9459518 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐cm H2O PEEP
Number of subjects: 22
Study 9459518 — intervention group
Group type: COMPARATOR
Intervention: No PEEP (Control)
Number of subjects: 22
Study 7630651 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder management by catheter (intermittent self‐catheterisation, indwelling urethral or suprapubic catheter)
Number of subjects: 70
Study 7630651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent self‐catheterisation
Number of subjects: 70
Study 7630651 — intervention group
Group type: COMPARATOR
Intervention: Voiding by reflex or straining
Number of subjects: 70
Study 2775152 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training (SST)
Number of subjects: 74
Study 2775152 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational emotive therapy (RET)
Number of subjects: 74
Study 2775152 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 74
Study 340390 — intervention group
Group type: EXPERIMENTAL
Intervention: Teorema (420 mg/day for 21 days)
Number of subjects: 24
Study 340390 — intervention group
Group type: EXPERIMENTAL
Intervention: Teorema (210 mg/day for 21 days)
Number of subjects: 24
Study 340390 — intervention group
Group type: COMPARATOR
Intervention: Indometacin (150 mg/day for 21 days)
Number of subjects: 24
Study 340390 — intervention group
Group type: COMPARATOR
Intervention: Indometacin (75 mg/day for 21 days)
Number of subjects: 24
Study 31054484 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib (130 mg) plus atorvastatin (40 mg)
Number of subjects: 100
Study 31054484 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus atorvastatin (40 mg)
Number of subjects: 100
Study 29033985 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 50
Study 29033985 — intervention group
Group type: COMPARATOR
Intervention: Sham group (placebo interventions)
Number of subjects: 50
Study 26480546 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy group (acupuncture + SSRIs)
Number of subjects: 90
Study 26480546 — intervention group
Group type: COMPARATOR
Intervention: Medication group (SSRIs only)
Number of subjects: 90
Study 23834817 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (20 μg/kg)
Number of subjects: 10
Study 23834817 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-derived factor VII (25 IU/kg)
Number of subjects: 10
Study 23834817 — intervention group
Group type: COMPARATOR
Intervention: Activated factor VII
Number of subjects: 10
Study 21747013 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered behavioral management
Number of subjects: 593
Study 21747013 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse- and physician-administered medication management
Number of subjects: 593
Study 21747013 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (behavioral + medication management)
Number of subjects: 593
Study 21747013 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 593
Study 19187367 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-delivered partner medication (PDPM)
Number of subjects: 467
Study 19187367 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient referral
Number of subjects: 467
Study 19187367 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal testing kit (PTK)
Number of subjects: 467
Study 16393297 — intervention group
Group type: EXPERIMENTAL
Intervention: Laxative (polyethylene glycol 3350 oral solution)
Number of subjects: 48
Study 16393297 — intervention group
Group type: EXPERIMENTAL
Intervention: Laxative and tegaserod
Number of subjects: 48
Study 14702232 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-Way Communication Checklist (2-COM)
Number of subjects: 134
Study 14702232 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 134
Study 12898306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate combined with alfacalcidol (cyclical etidronate plus alfacalcidol 1 Ig daily continuously)
Number of subjects: 40
Study 12898306 — intervention group
Group type: COMPARATOR
Intervention: Cyclical etidronate (oral etidronate 200 mg daily for 2 weeks every 3 months)
Number of subjects: 40
Study 10193418 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8+CD28+ T lymphocytes
Number of subjects: 46
Study 10193418 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8+CD28- T lymphocytes
Number of subjects: 46
Study 10193418 — intervention group
Group type: EXPERIMENTAL
Intervention: CD38+ in CD8bright cells
Number of subjects: 46
Study 10193418 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy initiation
Number of subjects: 46
Study 8525072 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid group (triamcinolone 200 mg i.v. within 4 h after trauma, followed by 3 x 40 mg/day i.v. for 4 days, and 3 x 20 mg/day i.v. for a further 4 days)
Number of subjects: 396
Study 8525072 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (injections without active drug)
Number of subjects: 396
Study 8525072 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid group (in patients with focal lesion and Glasgow Coma Score < 8)
Number of subjects: 396
Study 8525072 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (in patients with focal lesion and Glasgow Coma Score < 8)
Number of subjects: 396
Study 2271436 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.035 mg/kg
Number of subjects: 80
Study 2271436 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.05 mg/kg
Number of subjects: 80
Study 2271436 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.07 mg/kg
Number of subjects: 80
Study 2271436 — intervention group
Group type: COMPARATOR
Intervention: Control (no atracurium)
Number of subjects: 80
Study 6989226 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC) users
Number of subjects: 0
Study 6989226 — intervention group
Group type: COMPARATOR
Intervention: Sucrose load (1 g/kg)
Number of subjects: 0
Study 6989226 — intervention group
Group type: COMPARATOR
Intervention: Diet containing 51% carbohydrate (sucrose or wheat starch)
Number of subjects: 0
Study 6989226 — intervention group
Group type: COMPARATOR
Intervention: Time effect
Number of subjects: 0
Study 6989226 — intervention group
Group type: COMPARATOR
Intervention: OC-time interaction
Number of subjects: 0
Study 6989226 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak levels of glucose and insulin
Number of subjects: 0
Study 6989226 — intervention group
Group type: COMPARATOR
Intervention: Insulin/glucagon ratio
Number of subjects: 0
Study 31156199 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention for 8 weeks
Number of subjects: 83
Study 31156199 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 83
Study 28170104 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted mindfulness intervention plus treatment as usual (n = 20)
Number of subjects: 31
Study 28170104 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (n = 11)
Number of subjects: 31
Study 26329790 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg (day 1)
Number of subjects: 12
Study 26329790 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg (day 3)
Number of subjects: 12
Study 26329790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23484610 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended rehabilitation program (ERP) for socially vulnerable patients
Number of subjects: 508
Study 23484610 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation program (SRP) for socially vulnerable patients
Number of subjects: 508
Study 23484610 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation program (SRP) for socially non-vulnerable patients
Number of subjects: 508
Study 21085961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoplasty
Number of subjects: 155
Study 21085961 — intervention group
Group type: COMPARATOR
Intervention: Conventional angioplasty
Number of subjects: 155
Study 19245300 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/HCT 300/25 mg
Number of subjects: 722
Study 19245300 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/HCT 150/25 mg
Number of subjects: 722
Study 19245300 — intervention group
Group type: COMPARATOR
Intervention: HCT 25 mg
Number of subjects: 722
Study 17342794 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment applied for 1 week
Number of subjects: 96
Study 17342794 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment applied for a further week (if no difference observed)
Number of subjects: 96
Study 17342794 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroid (child's usual treatment)
Number of subjects: 96
Study 15109518 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg parecoxib
Number of subjects: 14
Study 15109518 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg paracetamol
Number of subjects: 14
Study 15109518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11822763 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic innovations tested in RCTs
Number of subjects: 136
Study 11822763 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients enrolled in RCTs
Number of subjects: 136
Study 11822763 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs analyzed according to intention-to-treat (ITT)
Number of subjects: 136
Study 11822763 — intervention group
Group type: EXPERIMENTAL
Intervention: Power analysis (beta error) reported
Number of subjects: 136
Study 11822763 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate concealment of treatment allocation
Number of subjects: 136
Study 11822763 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed description of patient withdrawals
Number of subjects: 136
Study 11822763 — intervention group
Group type: EXPERIMENTAL
Intervention: Double blind RCTs with appropriate methodology description
Number of subjects: 136
Study 9260076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad lib smoking exposure
Number of subjects: 16
Study 9260076 — intervention group
Group type: COMPARATOR
Intervention: 0 puffs exposure
Number of subjects: 16
Study 9260076 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater prior exposure (2, 6, or 12 puffs)
Number of subjects: 16
Study 9260076 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures
Number of subjects: 16
Study 7942262 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Pomeroy tubal ligation
Number of subjects: 44
Study 7942262 — intervention group
Group type: COMPARATOR
Intervention: Minilaparotomy Pomeroy tubal ligation
Number of subjects: 44
Study 30567590 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia (MTH; 32.0 °C-34.0 °C)
Number of subjects: 79
Study 27229470 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection and Lidocaine (IS)
Number of subjects: 106
Study 27229470 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid with distension (ISD)
Number of subjects: 106
Study 27229470 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 106
Study 24487691 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (T)
Number of subjects: 424
Study 24487691 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (L)
Number of subjects: 424
Study 24487691 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-years Tamoxifen, 3-years Letrozole (TL)
Number of subjects: 424
Study 24487691 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-years Letrozole, 3-years Tamoxifen (LT)
Number of subjects: 424
Study 24487691 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 424
Study 22712469 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA replacement therapy (50 mg day(-1))
Number of subjects: 92
Study 22712469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 20576633 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% oxygen
Number of subjects: 39
Study 20576633 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% oxygen
Number of subjects: 39
Study 20576633 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 39
Study 17823766 — intervention group
Group type: EXPERIMENTAL
Intervention: Allicor (time-released garlic powder tablet)
Number of subjects: 60
Study 16632234 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular insulin sliding scale
Number of subjects: 43
Study 16632234 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro insulin sliding scale
Number of subjects: 43
Study 12810472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal furosemide
Number of subjects: 170
Study 12810472 — intervention group
Group type: COMPARATOR
Intervention: No therapeutic treatment
Number of subjects: 170
Study 12810472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mometasone furoate
Number of subjects: 170
Study 10980226 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 0
Study 10980226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8979159 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplement of ascorbate, alpha‐tocopherol and beta‐carotene
Number of subjects: 7
Study 8979159 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 7
Study 1350882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent transdermal nitrate therapy (patch removed at night, mean patch-off period 10 hours)
Number of subjects: 85
Study 1350882 — intervention group
Group type: COMPARATOR
Intervention: Continuous transdermal nitrate therapy (10 mg/24 hours)
Number of subjects: 85
Study 3911965 — intervention group
Group type: EXPERIMENTAL
Intervention: Galphimia D6
Number of subjects: 164
Study 3911965 — intervention group
Group type: COMPARATOR
Intervention: Galphimia dilution 10(-6)
Number of subjects: 164
Study 3911965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 30590438 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to high cumulative occupational physical activity (OPA) with low leisure-time physical activity (LTPA)
Number of subjects: 5243
Study 30590438 — intervention group
Group type: EXPERIMENTAL
Intervention: High occupational physical activity (OPA) with low leisure-time physical activity (LTPA)
Number of subjects: 5243
Study 30590438 — intervention group
Group type: COMPARATOR
Intervention: Low occupational physical activity (OPA) and high leisure-time physical activity (LTPA)
Number of subjects: 5243
Study 29943445 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 184
Study 29943445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 26980905 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode Laser Stapedotomy (DLS)
Number of subjects: 60
Study 26980905 — intervention group
Group type: COMPARATOR
Intervention: Conventional Manual Stapedotomy (CMS)
Number of subjects: 60
Study 24247229 — intervention group
Group type: COMPARATOR
Intervention: Anesthesiology program directors
Number of subjects: 127
Study 24247229 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery program directors
Number of subjects: 127
Study 22714699 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 145 (monoclonal antibody inhibitor of PCSK9)
Number of subjects: 0
Study 22714699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20624650 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous mite allergoid immunotherapy (SCIT) plus fluticasone propionate (FP)
Number of subjects: 65
Study 20624650 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) therapy alone
Number of subjects: 65
Study 17389534 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision aid
Number of subjects: 497
Study 17389534 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-based decision aid
Number of subjects: 497
Study 17389534 — intervention group
Group type: COMPARATOR
Intervention: Control (no previsit education)
Number of subjects: 497
Study 15625423 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplemented enteral formula
Number of subjects: 80
Study 15625423 — intervention group
Group type: COMPARATOR
Intervention: Nonsupplemented formula
Number of subjects: 80
Study 15625423 — intervention group
Group type: COMPARATOR
Intervention: Glycine supplemented enteral formula
Number of subjects: 80
Study 15625423 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including glutamine, glycine, and nonsupplemented formula)
Number of subjects: 80
Study 12088809 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 L/min fresh gas flow
Number of subjects: 56
Study 12088809 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 L/min fresh gas flow
Number of subjects: 56
Study 9789512 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 25